Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.W | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Timeframe for evaluation

<< Previous

Bullboard Posts

Next >>

Comment by greaterfoolFredon Sep 05, 2020 5:19pm

189 Views

Post# 31515863

RE:RE:RE:RE:RE:RE:RE:Timeframe for evaluation

Yes, but for NMIBC the application is topical; very little enters the bloodstream. For the treatment of covid, or internal cancers the drug will have to be given by iv into the bloodstream. Dr. Coombs is talking about efficacy in the nanomolar range. TLD-1433 has a molecular weight of about 1000, so for example, 100 nanomolar works out to about 100 ug/L. So the dose level in an animal would be about 100 ug/kg body weight. This would be pretty safe in rats, where the NOAEL was found to be 6mg/kg; that's 60 times higher. This is good. I hope my math is right!

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for May 22, 2024